Apollo Endosurgery, Inc.（纳斯达克股票代码：APEN）认为空头利率大幅增加

Apollo Endosurgery, Inc. (NASDAQ:APEN – Get Rating) was the recipient of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,380,000 shares, an increase of 181.3% from the January 15th total of 490,600 shares. Based on an average trading volume of 1,460,000 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analysts Forecast Growth

APEN has been the topic of a number of analyst reports. Stifel Nicolaus cut shares of Apollo Endosurgery from a "buy" rating to a "hold" rating and set a $10.00 target price on the stock. in a research report on Tuesday, January 3rd. Cowen lowered Apollo Endosurgery from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $13.00 to $10.00 in a research report on Monday, January 23rd. Finally, Lake Street Capital downgraded Apollo Endosurgery from a "buy" rating to a "hold" rating and lowered their price objective for the company from $14.00 to $10.00 in a research report on Wednesday, November 30th.

Get Apollo Endosurgery alerts:

Institutional Investors Weigh In On Apollo Endosurgery

Several institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its holdings in Apollo Endosurgery by 4.5% in the fourth quarter. Bank of America Corp DE now owns 40,965 shares of the biotechnology company's stock valued at $408,000 after acquiring an additional 1,758 shares in the last quarter. HRT Financial LP bought a new position in shares of Apollo Endosurgery in the 4th quarter worth approximately $803,000. GWM Asset Management Ltd purchased a new position in shares of Apollo Endosurgery in the 4th quarter valued at approximately $1,652,000. BCK Capital Management LP bought a new stake in shares of Apollo Endosurgery during the fourth quarter valued at approximately $1,386,000. Finally, UBS Group AG grew its stake in Apollo Endosurgery by 893.8% in the fourth quarter. UBS Group AG now owns 35,328 shares of the biotechnology company's stock worth $352,000 after purchasing an additional 31,773 shares during the period. Hedge funds and other institutional investors own 76.01% of the company's stock.

Apollo Endosurgery Stock Performance

Apollo Endosurgery stock opened at $9.93 on Friday. The company has a current ratio of 6.00, a quick ratio of 4.98 and a debt-to-equity ratio of 1.26. The firm has a market cap of $472.17 million, a P/E ratio of -9.74 and a beta of 2.30. Apollo Endosurgery has a 1-year low of $3.49 and a 1-year high of $10.30. The firm has a 50-day moving average of $9.92 and a 200-day moving average of $7.43.

About Apollo Endosurgery

(Get Rating)

Apollo Endosurgery, Inc is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System.

Featured Stories

• Get a free copy of the StockNews.com research report on Apollo Endosurgery (APEN)
• MarketBeat Week in Review – 2/6 – 2/10
• Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
• The Bottom Is In For Cloudflare Stock
• 3 Tickers Leading a Meme Stock Revival
• Microsoft-Activision Blizzard Merger: Navigating Risk and Reward

Receive News & Ratings for Apollo Endosurgery Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery and related companies with MarketBeat.com's FREE daily email newsletter.